Institutional Biosafety Committee
Meeting Minutes

The meeting was called to order on 4/28/2026 at 11:30AM. A quorum was present. The meeting was held via Zoom and in-person (Melville Library – 5th Floor, Room W5530). The meeting was open.

Attendance
Voting Members Present:
Nicholas Carpino
Jeronimo Cello
Jorge Escobar
Hwan Kim
Christopher Kuhlow
Alyssa Tuthill
Dafang Wang

Non-Voting Attendees, Staff and Guests Present:
Rebecca Dahl
Lu-Ann Kozlowski
Aimee Minton
Terrence Rusch

Recording:
Erin Augello

Items
1. **Meeting called to order at 11:30AM**

2. **Next meeting date and general announcements**

The next meeting date is 5/19/2026. Dr. Carpino surveyed the assembled group to assess any conflict of interest or quorum issues. Members should recuse themselves and leave the room or Zoom meeting during the review of a study on which they have a conflict of interest.

3. **Review of minutes from last meeting**

Review type: **Full Committee Review**

Action: **Approved**
Effective date: **4/28/2026**
Vote: **Total = 7; For = 7; Opposed = 0; Abstained = 0**

4. Continuing reviews requiring IBC review
This section was reviewed and noted by the committee.

5. New studies for committee review

a. PROTO202600013 Translational Control in Diseases

PI:	Haojun Yang
Submission Type:	Initial Protocol
Safety Review Type:	Biosafety
Funding:	Name: Stony Brook University
Training:	PI and all laboratory staff have been trained
Applicable Section of the NIH Guidelines that the Research Falls Under	Section IIID
Containment Conditions:	BSL-2

Determination: Modifications Required
Modifications (If Applicable):
i. In Section: Protocol Team Members
Item 1. Please indicate whether PI is involved with procedures.
ii. In Section: Biohazards
Item 1. In #2, the protocol states, "No agents will be administered to humans or animals in this protocol," while some cells are proposed to be transplanted onto mice. Clarification is required.
iii. In Section: Recombinant or Synthetic Nucleic Acid Usage
Item 1. Please include NIH Section ("Yes" to Section D-III).
iv. In Section: Risk Group and Containment Practices
Item 1. Please change to RG3, due to use of lentivirus vector.
v. In Section: Exposure Assessment and Protective Equipment
Item 1. The current text focuses on risk minimization and containment practices rather than biological outcomes. Please revise the response to focus on the biological consequences of exposure or release to humans, animals, and the environment, and remove discussion of likelihood and containment practices, which are not responsive to this question. For lentiviral vectors, please include relevant consequences of exposure, including the potential for transduction of exposed cells, genomic integration, and insertional mutagenesis. In addition, the possibility exposure consequences of of replication-competent lentivirus (RCL) generation should be acknowledged, particularly when using second-generation systems. The use of VSV-G pseudotyping should also be considered, as it confers broad tropism and enables infection of both dividing and non-dividing cells. Finally, due to the use of human-derived cell lines, please explicitly acknowledge the potential for bloodborne pathogen exposure.

Effective Date: 4/30/2026
Project Expiration: 4/29/2027

Votes:

For:	7
Against:	0
Recused:	0
Absent:	3
Abstained:	0

b. PROTO202600015 Peptide Radiopharmaceuticals

PI:	Yubin Miao
Submission Type:	Initial Protocol
Safety Review Type:	Biosafety
Funding:	Name: National Cancer Institute, Grant Office ID: Funding Source ID: 7R01CA269221 Name: National Cancer Institute, Grant Office ID: Funding Source ID: 7R01CA225837
Training:	PI and all laboratory staff have been trained
Applicable Section of the NIH Guidelines that the Research Falls Under	Section IIID
Containment Conditions:	BSL-2

Determination: Approved
Modifications (If Applicable):
i. In Section: Basic Information
Item 4. Summary of research is very brief and does not include enough information. There is also no mention or description of rsNAM-related work. If rsNAM work (e.g., viral vectors, transfection, gene expression/knockdown/editing, etc.) is being conducted, then it must be described here. On the Biosafety Summary page, choose the correct option from the drop-down menu and provide requested information in all corresponding sections (for example, on the Recombinant/Synthetic Nucleic Acid Work Description page). If no rsNAM work is being conducted, this protocol does not require IBC approval.

Effective Date: 4/28/2026
Project Expiration: 4/27/2027

Votes:

For:	7
Against:	0
Recused:	0
Absent:	3
Abstained:	0

c. PROTO202600017 Multi-omics Research of GI Tract & Organoids

PI:	Lasha Gogokhia
Submission Type:	Initial Protocol
Safety Review Type:	Biosafety
Funding:	Stony Brook University, Grant Office ID: 910226-08, Funding Source ID: startup funds
Training:	PI and all laboratory staff have been trained

Applicable Section of the NIH Guidelines that the Research Falls Under	Section IIID
Containment Conditions:	BSL-2

Determination: Modifications Required
Modifications (If Applicable):
i. In Section: Basic Information
Item 4. Summary of research is very brief and does not include enough information. There is also no mention or description of rsNAM-related work. If rsNAM work (e.g., viral vectors, transfection, gene expression/knockdown/editing, etc.) is being conducted, then it must be described here. On the Biosafety Summary page, choose the correct option from the drop-down menu and provide requested information in all corresponding sections (for example, on the Recombinant/Synthetic Nucleic Acid Work Description page). If no rsNAM work is being conducted, this protocol does not require IBC approval.

Effective Date: 4/28/2026
Project Expiration: 4/27/2027

Votes:

For:	7
Against:	0
Recused:	0
Absent:	3
Abstained:	0

d. PROTO202600018 Centrosomes and Cilia Biology

PI:	Yue Liu
Submission Type:	Initial Protocol
Safety Review Type:	Biosafety
Funding:	Name: Stony Brook University, Grant Office ID: 1109270-14-63845
Training:	PI and all laboratory staff have been trained
Applicable Section of the NIH Guidelines that the Research Falls Under	Section IIID
Containment Conditions:	BSL-2

Determination: Approved
Modifications (If Applicable):
i. In Section: Team Members
Item 1. Please indicate whether PI is involved with procedures.
ii. In Section: Funding Sources
Item 1. Please provide Grants Office ID number.
iii. In Section: Primary cells or cell lines
Item 1. Human cell line RPE 1 should be listed as BSL2.
iv. In Section: Recombinant or Synthetic Nucleic Acid Work Description
Item 6. Tissue/cell culture: Vero and Expi293F should be listed here
v.In Section: Risk Group and Containment Practices
Item 1. Change to RG-3 due to lentiviral use.

vi. In Section: Exposure Assessment and Protective Equipment
Item 1. The response does not adequately address the question, which requests a description of the potential consequences of exposure or release. The current text focuses primarily on risk and containment measures. Please revise the response to focus on the potential outcomes of exposure or release to humans, animals, and the environment, rather than the likelihood of such events. The following issues are noted: 1) the consequences of exposure to lentiviral vectors are not addressed, including potential insertional mutagenesis and the possibility of replication-competent lentivirus generation; 2) the potential for bloodborne pathogen exposure from human-derived cell lines should also be explicitly acknowledged; 3) the consequences of exposure to Chlamydia trachomatis are not described. Please include relevant outcomes such as mucosal infection (e.g., conjunctivitis or urogenital infection) following accidental exposure; 4) PI states use of adenoviruses. Please clarify as they are not mentioned anywhere else in the protocol.

Effective Date: 4/30/2026
Project Expiration: 4/29/2027

Votes:

For:	7
Against:	0
Recused:	0
Absent:	3
Abstained:	0

6. Amendments requiring IBC review

a. AMEND202600042 Amendment as Part of Continuing Review

PI:	Aaron Neiman
Submission Type:	Amendment
Safety Review Type:	Biosafety
Funding:	None
Training:	Protocol team member needs to complete EHS training ELS003 and EOS004
Applicable Section of the NIH Guidelines that the Research Falls Under	Section IIID
Containment Conditions:	BSL-2

Determination: Approved
Modifications (If Applicable):
i. Please ensure training is up to date. Currently, A. Neiman, Coman, Dilmen, Kim, Park, Sanya, Zhang require ELS 003 and EOS 004.

Effective Date: 5/22/2026
Project Expiration: 5/21/2027

Votes:

For:	7
Against:	0

Recused:	0
Absent:	3
Abstained:	0

b. AMEND202600044 Addition of Primary Human ADPKD Cells and Administrative Update for Continuing Review

PI:	Karam Aboudehen
Submission Type:	Amendment
Safety Review Type:	Biosafety
Funding:	None
Training:	PI and all laboratory staff have been trained
Applicable Section of the NIH Guidelines that the Research Falls Under	Section IIID
Containment Conditions:	BSL-2

Determination: Approved
Modifications (If Applicable):
i. In Section: Protocol Team Members
Item 1. Please indicate role of each team member, in the column “Involved with Procedures”.
ii. In Section: Viruses and Prions AND Biosafety Hazards
Item 1. The designation “BSL-2+” is not a formally defined biosafety level and can be ambiguous without specifying the additional practices or containment measures that distinguish it from standard BSL-2. PI should clarify which specific enhanced BSL-2 practices or engineering controls are being implemented (e.g., additional PPE, respiratory protection, procedural restrictions, or containment equipment), or revise the classification to standard BSL-2 if no such enhancements are defined.
iii. In Section: Exposure Assessment and Protective Equipment
Item 1. PI mentions "Replication deficient adenovirus...." in the last sentence. This should be removed if adenovirus is not being used. If adenovirus is being used, other sections of the protocol (e.g. Viruses and Prions page) need to be corrected to include its use. In addition, human derived materials are being used and therefore the consequence of possible exposure to bloodborne pathogens should be described. Finally, the consequence of possible exposure to AAV should be described (e.g. possible effects of insertional mutagenesis, etc.).

Effective Date: 6/18/2026
Project Expiration: 6/17/2027

Votes:

For:	7
Against:	0
Recused:	0
Absent:	3
Abstained:	0

7. Review of incidents
None

8. Review of other agenda items
None

9. Inspection results
All inspections and responses were summarized by Mr. Kuhlow and reviewed and noted by the committee.

10. Discussion items/readings (major and minor points of order)
The committee members were given information about minor changes to the Standard Operating Procedures. They will be sent a copy of the SOPs in order to review and give feedback. As a reminder, Rebecca Dahl also went over the procedure for lapsed protocols.

11. Meeting adjourned at **12:29 PM**